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Background: Injecting drug users are at increased risk for harmful effects compared to non-injecting drug users.
Some studies have focused on differences in characteristics between these two groups (e.g., housing, overall
health). However, no study has investigated the specific Dutch situation which in the last years has seen a decrease
in homelessness among problematic hard-drug users and an increasing focus on physical health in low-threshold
addiction care. The purpose of this study was to determine differences in sociodemographic, drug use and health
characteristics between never-injecting (NIDUs), former-injecting (FIDUs) and current-injecting drug users (IDUs) and
describe injecting practices.
Methods: A total of 202 problematic hard-drug users (NIDU = 64; FIDU = 76; IDU = 62) were recruited from 22 low-
threshold care facilities, including drug consumption rooms, methadone maintenance treatment, heroin-assisted
therapy, day shelter and/or night shelter, supported housing and day activity centres. Data were collected on-site
through structured face-to-face interviews.
Results: Results indicate that IDUs represented a separate group of problematic hard-drug users, with distinct
sociodemographic and drug use characteristics. Overall, IDUs appeared to be the group with least favourable
characteristics (unstable housing/homelessness, illegal activities, polydrug use) and NIDUs appeared to have the
most favourable characteristics (stable housing, help with debts, less polydrug use). The FIDU group lies somewhere
in between. The three groups did not differ significantly in terms of health. Regarding injecting practices, results
showed that majority of IDUs had injected drugs for over 10 years and IDUs injected heroin, cocaine, amphetamine
and/or methadone in the past 6 months. Sharing syringes was not common. A quarter reported public injecting.
Conclusions: Unstable housing and homelessness are related to (former) injecting drug use, and stable housing is
related to never-injecting drug use. Our study suggests that the number of ‘new’ IDUs is low. However, public
injecting among IDUs is not uncommon and is associated with unstable housing. This emphasizes the potential of
housing projects as a component of harm reduction measures. Therefore, prevention of (risks associated with)
injecting drug use and supported housing programmes for problematic hard-drug users deserve the continuous
attention of policymakers and professionals in low-threshold addiction care.
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It is widely recognized that injecting drug use is the most
harmful route of administration [1,2]. Compared to non-
injecting drug users, injecting drug users are at increased
risk for vein damage [3,4], fatal and non-fatal overdoses
[5-7] and the transmission of blood-borne infectious dis-
eases mainly due to sharing injection equipment [8-22].
According to estimates based on 2008 data, there are
approximately 17,700 problematic opiate users in the
Netherlands [23]. The number of injectors has decreased
over the past 15 years due to the high mortality rate and
the low rate of initiation into injecting drug use [24,25].
Compared to other European countries, the Netherlands
has (by far) the lowest percentage of injectors [26]: an
estimated 7%–13% of the problematic opiate users inject
drugs [23,26].
Although many studies have investigated injecting and
non-injecting drug users, few have focused on differ-
ences in characteristics between these two groups. Stud-
ies comparing injectors and non-injectors have been
performed in, for example, North America, Europe and
Asia and have reported a variety of differences in charac-
teristics. In terms of sociodemographic characteristics,
some studies suggest that non-injectors are more likely
to be younger [16,19,27] and female [27]. However, other
studies found no significant differences between injec-
tors and non-injectors with regard to age and gender
[10,28]. Unstable housing and income from illegal activ-
ities are more likely to occur among injectors [10,19].
Studies also indicate that injectors have a lower educa-
tion level and are more likely to drop out of school com-
pared to non-injectors [16,28,29]. With regard to drug
use characteristics, injectors tend to start using drugs at a
younger age [27,28], report a longer duration of drug use
[16,19,27], a higher frequency of use [10,27] and higher
rates of dependence [29] compared to non-injectors. In-
jectors are also more likely to use drugs other than heroin,
such as cocaine and/or amphetamine [19,27]. In terms of
health characteristics, injectors more frequently report
poor or fair overall health [10] and report higher levels of
somatisation and anxiety symptoms [19]. However, other
studies show that non-injectors are more likely to experi-
ence mental health problems than injectors [10].
As mentioned, some studies have aimed to identify dif-
ferences between injectors and non-injectors. However, no
study has investigated the specific situation in the
Netherlands. Therefore, little is known about differences
in sociodemographic, drug use and health characteristics
between injectors and non-injectors in the Netherlands.
Furthermore, in the last decade, two notable develop-
ments in the Netherlands make a Dutch study of interest.
First, intensive efforts from the government, municipality
and social care have led to a decrease in the number of
homeless problematic drug users [30,31]. Studies emphasizethe potentially positive impact of stable housing on drug-
related health, e.g. a decrease in drug use and reduced risk
of needle/syringe sharing and unprotected sex [31-34].
Second, in the Netherlands, there seems to be an increas-
ing focus on physical health in low-threshold addiction
care, illustrated by the development and use of guidelines,
the implementation of HCV screening and the increased
number of medical personnel working in these facilities
[35-39]. Since nearly all problematic hard-drug users are
clients in addiction care, this may have a positive impact
on drug-related health. With these developments in mind,
the present study aims to investigate key differences
between never-injecting drug users (NIDUs), former-
injecting drug users (FIDUs) and current-injecting drug
users (IDUs) in the Netherlands. More specifically, we
examine differences in sociodemographic, drug use and
health characteristics between these groups. We also de-
scribe the injecting practices of IDUs because of their
strong association with health outcomes.
Methods
Procedure
The sample consisted of 202 problematic hard-drug users
and was selected using convenience sampling. Participants
were recruited in low-threshold addiction care facilities
which all target problematic hard-drug users, including
drug consumption rooms, methadone maintenance treat-
ment, heroin-assisted therapy, day shelter and/or night
shelter, supported housing and day activity centres. These
facilities reach both injecting and non-injecting problem-
atic hard-drug users in the Netherlands (there are no facil-
ities specifically targeting injecting drug users). Since
nearly all problematic hard-drug users are clients of low-
threshold care facilities (86%) [23,40] and open drug
scenes seem to have disappeared [25,41], these facilities
were chosen for recruitment activities. The selection of
low-threshold care facilities was made with the assistance
of members of the Network of Infectious Diseases and
Harm Reduction (NIHR) [42], in which all 11 Dutch re-
gional addiction care organizations are represented. Mem-
bers have an adequate view of the care provided and the
corresponding target group in their region. Therefore, the
selection of facilities can be characterized as a good reflec-
tion of the Dutch low-threshold care facilities for prob-
lematic hard-drug users. The NIHR is coordinated by the
Trimbos Institute and is financially supported by the Min-
istry of Health, Welfare and Sport. All approached facil-
ities agreed to participate in the study, which resulted in
22 recruitment sites located in all 12 provinces in the
Netherlands. Twelve facilities were ‘stand-alone’ services,
namely supported housing (n = 4), methadone mainten-
ance treatment (n = 4), day activity centres (n = 2), heroin-
assisted therapy (n = 1) and drug consumption rooms
(n = 1). The remaining facilities (n = 10) were ‘integrated’:
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These facilities consisted of different combinations of
methadone maintenance treatment, heroin-assisted ther-
apy, drug consumption rooms and day and night shelter.
Face-to-face interviews were conducted by four trained
Trimbos Institute researchers who visited each facility in
teams of two or three for 4–8 h. Before their visit, two
posters were distributed in the facility to inform and en-
gage drug users in general and IDUs in particular to par-
ticipate in the study. Because of the low prevalence,
IDUs were intentionally overrepresented in order to pro-
vide a sufficiently large number for comparison pur-
poses. Besides that, we were especially interested in
injection practices in this population. Upon arrival at the
facility, the researchers started recruiting participants for
the interview, in most cases, with the help of the attend-
ing staff. Clients were eligible for participation if they
had a minimum age of 18 years and had a sufficient
command of the Dutch language. All clients who were
willing and able to participate were included. Partici-
pants gave informed consent and were assured of ano-
nymity at the beginning of the interview. They received
€5 after the interview was completed. The interview
lasted 30–60 min on average.
Instrument
Participants were interviewed using a structured question-
naire which included questions on sociodemographic
background, drug use patterns and (mental) health char-
acteristics. IDUs were asked about injection behaviour in
the past 6 months.
Two questions were used to differentiate between
NIDUs, FIDUs and current IDUs [43-46]: ‘Have you
ever, even once, injected any drug?’ and ‘In the past
6 months, have you injected any drug?’ Participants were
categorized as NIDU (never injected drugs), FIDU (have
injected drugs but not in the last 6 months) or IDU
(injected drugs in the past 6 months). Sociodemographic
characteristics included sex, age, ethnicity (according to
Statistics Netherlands (CBS): native Dutch, Western im-
migrants, non-Western immigrants), highest level of
education completed, legal identity (passport or identifi-
cation card), currently paid or volunteer work, current
illegal sources of income, stable housing, current debt
situation, estimated debt amount and debt help. Illegal
income was defined as income generated in the past
month by property crime, violent crime, drug dealing,
prostitution or begging. To measure ‘stable housing’, we
asked participants about their current housing status: in-
dependent housing/rented room, sheltered housing with
ambulatory support, sheltered housing with 24/7 support,
temporary housing (squat, shelter, staying with friends or
family) or homeless. The first three categories were de-
fined as stable housing. In terms of health characteristicsa,we asked the participants how many times they had visited
a physician for physical complaints and if they had visited
a psychiatrist or another mental health care professional
in the past 12 months. General health is based on a health
question measured on a five-point scale about self-
perceived health: ‘How is your health in general?’ [47].
The first two categories (‘very good’ or ‘good’) were classi-
fied as ‘good perceived health’. Drug use characteristics
were measured by the number of days a particular drug
had been used in the past 30 days, with reference to the
following substances: heroin, methadone, cocaine/crack,
amphetamine, non-prescribed tranquilizers, cannabis and
alcohol. Respondents were divided into two categories:
daily users (≥20 days/month) and non-daily users (<20 days/
month). Current injection practices included age at first
injection, duration of injecting, type of drugs injected,
main drug injected, injection frequency, main place of in-
jection (physical location) and risk behaviour. Based on
classifications described by Harris et al. [48], injection fre-
quency in the past 6 months was divided into three cat-
egories: low-frequency injectors (1–60 injections), less
than daily injectors (>60 injections, but not on a daily
basis) and daily injectors (>182 injections). Risk behaviour
indicators were syringe sharing and public injecting in the
past 6 months. Furthermore, we asked participants if they
had ever attempted to stop injecting.
Data analyses
Differences between NIDUs, FIDUs and IDUs in socio-
demographic, drug use and health characteristics were
analyzed using chi-square tests (proportions) with 95%
confidence levels (CI). A p value less than 0.05 was con-
sidered significant. All statistical analyses were per-
formed using Statistical Package for the Social Sciences
version 19 (SPSS 19).
Results
Of the 202 participating problematic hard-drug users, 64
(32%) were NIDUs, 76 (38%) were FIDUs and 62 (31%)
were IDUs.
Differences between NIDUs, FIDUs and IDUs
Sociodemographic and health characteristics of NIDUs,
FIDUs and IDUs are presented in Table 1, and drug use
characteristics are presented in Table 2. Specifics on
IDUs and injecting characteristics are presented in the
next paragraph. Regarding FIDUs, the mean time since
participants last injected was 10.6 years ago (median
8.0 years), and the mean duration of injecting was 12.2 years
(median 10.5 years).
Sociodemographic characteristics
NIDUs were less likely to be native Dutch than FIDUs and
IDUs (41%, 66% and 63%, respectively) and were more
Table 1 Sociodemographic and health characteristics of NIDUs, FIDUs and current IDUs
Characteristic Total NIDU FIDU IDU Test statistic
Pn (%) n (%) n (%) n (%)
202 (100) 64 (32) 76 (38) 62 (31)
Sociodemographic
Male 164 (81) 49 (77) 62 (82) 53 (86) 0.438
Age, years 0.343
≤39 41 (20) 13 (20) 15 (20) 13 (21)
40–49 89 (44) 27 (42) 29 (38) 33 (53)
≥50 72 (36) 24 (38) 32 (42) 16 (26)
Ethnicity 0.000***
Native Dutch 115 (57) 26 (41) 50 (66) 39 (63)
Western immigrant 46 (23) 9 (14) 21 (28) 16 (26)
Non-Western immigrant 41 (20) 29 (45) 5 (7) 7 (11)
Possession of passport or identification card 173 (86) 55 (86) 69 (91) 49 (79) 0.146
High school completion 126 (62) 39 (61) 48 (63) 39 (63) 0.959
Stable housing 153 (76) 56 (88) 55 (72) 42 (68) 0.024*
Social welfare payment 192 (95) 61 (95) 71 (93) 60 (97) 0.660
Paid or volunteer work 84 (42) 28 (44) 29 (38) 27 (44) 0.745
Illegal income 53 (26) 10 (16) 17 (22) 26 (42) 0.003**
Debts (in euro) 145 (71) 50 (78) 51 (67) 44 (71) 0.348
0–10,000 22 (15) 8 (16) 11 (22) 3 (7)
10,001–100,000 62 (43) 19 (38) 25 (49) 18 (41)
100,001–500,000 49 (34) 17 (34) 11 (21) 21 (48)
>500,000 9 (6) 4 (8) 3 (6) 2 (5)
Unknown 3 (2) 2 (4) 1 (2) -
Debt help 96 (66) 36 (72) 38 (75) 22 (50) 0.024*
Health
Good perceived health 86 (43) 27 (42) 33 (43) 26 (42) 0.982
Visit physician for physical complaints (past 12 months) 136 (67) 44 (69) 50 (66) 42 (68) 0.930
1–4 88 (65) 24 (56) 33 (66) 31 (74) 0.271
5–10 29 (22) 11 (26) 9 (18) 9 (21)
>10 18 (13) 8 (19) 8 (16) 2 (5)
Visit psychiatrist/other mental health care professional (past 12 months) 70 (35) 19 (30) 26 (34) 25 (40) 0.453
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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respectively). Furthermore, a significantly higher percent-
age of NIDUs had stable housing compared to FIDUs and
IDUs (88%, 72% and 68%, respectively). IDUs were more
likely to generate income from illegal activities than FIDUs
and NIDUs (42%, 22% and 16%, respectively), particularly
from drug dealing, property crime and begging. Although
no significant differences were found in the proportion of
respondents who had debts and the amount of debts, sig-
nificantly less IDUs reported that they had help with debts
compared with FIDUs and NIDUs (50%, 75% and 72%,
respectively).Health characteristics
There were no significant differences between the three
groups in terms of health characteristics.
Drug use characteristics
Proportionally, more IDUs reported heroin use in the
past month compared to FIDUs and NIDUs (92%, 54%
and 63%, respectively). The same applies to alcohol use
(71%, 47% and 56%, respectively) and amphetamine use
(27%, 7% and 11%, respectively). Compared to FIDUs
and IDUs, NIDUs were less likely to use methadone
(93%, 92% and 69%, respectively) and non-prescribed
Table 2 Drug use in the past month of NIDUs, FIDUs and current IDUs
Drug Total NIDU FIDU IDU Test statistic
Pn (%) n (%) n (%) n (%)
202 (100) 64 (32) 76(38) 62 (31)
Methadone 172 (85) 44 (69) 71 (93) 57 (92) 0.000***
Cocaine 149 (74) 45 (70) 53 (70) 51 (82) 0.188
Heroin 138 (68) 40 (63) 41 (54) 57 (92) 0.000***
Cannabis 120 (59) 33 (52) 46 (61) 41 (66) 0.242
Alcohol 116 (57) 36 (56) 36 (47) 44 (71) 0.020*
Non-prescribed tranquilizers 32 (16) 3 (5) 15 (20) 14 (23) 0.011*
Amphetamine 29 (14) 7 (11) 5 (7) 17 (27) 0.002**
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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was used 28.8 days on average in the past month; alcohol,
18.2 days; cannabis, 18.0 days; heroin, 17.5 days; cocaine,
14.1 days; non-prescribed tranquilizers, 13.0 days; and am-
phetamine, 11.7 days. No significant differences were
found between the three groups in the proportion of non-
daily and daily users (<20 and ≥20 days per month) for
each substance. The respondents used a mean of 3.7 (of
the seven mentioned) substances in the past month (me-
dian 4 substances), showing that, along with the number
of days that substances were used, respondents can be cat-
egorized as polydrug users.Current injection practices of IDUs
Current injection practices of IDUs are presented in
Table 3. Among IDUs, age at first injection ranged from
13 to 58 years. About half of the sample (45%) had first
injected before the age of 20; 31%, between 20 and
29 years; 11%, between 30 and 39 years; and 13%, above
age 40 years. The majority have been injecting drugs for
more than 10 years (76%) and had, at least once,
attempted to stop injecting (84%). Five IDUs have been
injecting drugs for 2 years or less. Almost all IDUs (97%)
reported injecting heroin in the past 6 months, followed
by cocaine (60%), amphetamine (29%) and methadone
(18%). Heroin was by far the main drug injected (60%),
and more than half of the sample (61%) indicated their
home as the main place where injecting took place. Syr-
inge sharing was not common (10%). In the past 6 months,
24% of the IDUs reported public injecting. With regard to
injection frequency, 48% of IDUs were low-frequency in-
jectors, 18% were less than daily injectors and 32%
injected on a daily basis.Discussion
This study investigated the differences between NIDUs,
FIDUs and IDUs in the Netherlands, with a special focus
on IDUs due to their increased risk of harm.Differences between NIDUs, FIDUs and IDUs
Our findings indicate that IDUs represent a separate
group of problematic hard-drug users, with distinct
sociodemographic and drug use characteristics. Overall,
IDUs appear to be the group with the least favourable
sociodemographic and drug use characteristics, the
NIDU group has the most favourable characteristics and
the FIDUs fall somewhere in between. However, the
three groups did not differ in terms of health character-
istics. Results show that NIDUs are more likely than
FIDUs and IDUs to be non-Western immigrants. A pos-
sible explanation is that injecting drug use may—at least
in part—be inhibited by cultural factors and that other
conditions (e.g. social cohesion, being distinctive as a
group from ‘white junkie injectors’ [49]) were favourable
for the popularity of the chasing ritual [1,49]. Another
finding is that unstable housing is more frequent among
IDUs. This is in agreement with previous studies sug-
gesting a link between injecting drug use and bad hous-
ing status or homelessness [10,33,50-53]. We found that
IDUs are more likely to generate income from illegal ac-
tivities such as drug dealing, crime against property and
begging. Other studies reported similar results [10,19].
While no difference was found between the groups with
respect to debts, the results did show that only half of
the IDUs receive help with debts as compared to about
75% in the other groups. This finding is difficult to ex-
plain. Additional analyses showed that problematic
hard-drug users with unstable housing are less likely to
receive debt help compared to those with stable housing
(45% and 74%, respectively; p = 0.001). However, being a
NIDU, FIDU or IDU does not seem to be meaningful
within this context. IDUs seem to have more unfavour-
able drug use characteristics compared to NIDUs and
FIDUs. Although there were no substantial differences
between the average days of drug use, significantly, more
IDUs report the use of heroin, alcohol and amphet-
amine. Polydrug use is common among IDUs, as evi-
denced by the high proportions of IDUs that used
Table 3 Current injection characteristics of IDUs (n = 62)
Current injection characteristics n (%)
Injection practices






0–2 years 5 (8)
3–9 years 10 (16)
10–19 years 14 (23)
≥ 20 years 33 (53)










Frequency of injecting (in past 6 months)
Low frequency (1–60 injections) 30 (48)
Less than daily (61–182 injections) 11 (18)
Daily (>182 injections) 20 (32)
Main place of injection (in past 6 months)
Home 38 (61)
Drug Consumption Room 11 (18)
Friends home 8 (13)
Other facilities (e.g. HAT) 3 (5)
Public places 2 (3)
Attempt(s) to stop injecting 52 (84)
Risk behaviour
Syringe sharing (in past 6 months) 6 (10)
Public injecting (in past 6 months) 15 (24)
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caine 82%, heroin 92%). This is in line with others who
found that proportionally more drug users who identi-
fied injecting as their main route of heroin use declared
to have (ever) used more than one drug in addition to
heroin [19,27], e.g. cocaine and benzodiazepines. The
three groups showed no differences in terms of health
characteristics, yet previous studies did identify health
differences [10,19]. These inconsistencies in findingsmay be due to differences in classifications used to dis-
tinguish between injectors and non-injectors. For in-
stance, Fischer et al. [10] found that significantly more
current non-injectors (i.e. those who had not injected in
the last 30 days) had good overall health compared to
current injectors (i.e. those who had injected in the last
30 days) and that mental health problems were more fre-
quent among current non-injectors. In contrast, Stohler
et al. [19] reported higher levels of somatisation and anx-
iety symptoms in heroin users who predominantly
injected compared to heroin users for whom chasing was
the preferred and most used route of heroin administra-
tion. Furthermore, this result might be explained by the
fact that, in the Netherlands, almost all problematic hard-
drug users, injectors as well as non-injectors, are clients of
low-threshold care facilities [23,40] in which the focus on
health has increased in recent years [37-39].
Injecting practices
Our findings suggest that the number of problematic
hard-drug users who recently initiated injecting is low.
The IDU group in our study mainly consists of long-
term injectors. More than 75% of the IDUs have been
injecting drugs for ≥10 years, while only five IDUs are
so-called ‘new injectors’, i.e. those injecting for ≤2 years
[54]. This is in line with other research showing a con-
tinuing decline in prevalence rates of IDUs over the last
decades [24-26].
Research in the Netherlands showed that amphet-
amine users hardly choose injection as route of adminis-
tration [55]. In our study, approximately 30% of the
IDUs had injected amphetamine in the past 6 months
which indicates that amphetamine injection is not un-
common among IDUs. As these studies took different
approaches (respectively amphetamine users and IDUs),
it is not clear if our result suggests an increased popular-
ity of injection as a route of administering amphetamine.
Future research should examine the prevalence of am-
phetamine injecting and identify motives for injecting.
Understanding the motives for injecting amphetamine
may contribute to the development of effective prevent-
ive interventions.
Because syringe or needle sharing is not common
among IDUs (10% in the past 6 months), the risk of
transmission of infectious diseases through sharing ap-
pears to be relatively small. This proportion seems to be
in line with previous estimates based on 16 surveys
reporting prevalence rates of 11%–30% of IDUs who had
borrowed syringes or needles from someone else [56].
Broad availability of needle and syringe exchange pro-
grammes (NSP) from which IDUs can obtain injecting
equipment easily and for no or low cost probably played
a substantial role in reducing syringe sharing. A rough
estimation suggests that, currently, there are about 150
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grammes and drug consumption rooms have probably
contributed to the reduction of risks associated with
injecting in public spaces [33,58]. However, our results
clearly indicate that public injecting is still a topic of
serious concern. About 25% of the IDUs in our sample
reported public injecting in the past 6 months. There is
evidence linking unstable housing/homelessness to inject-
ing in public spaces [34,53,59,60]. Additional analyses
showed that a higher proportion of IDUs living in unstable
housing conditions reported injecting in public places
compared to IDUs living in stable housing conditions
(40% and 17%, respectively). Although results did not
reach statistical significance (p = 0.06), housing may be a
factor that positively influences injecting practices, includ-
ing public injecting.
Limitations
Some limitations of the study should be considered.
First, generalizability of the results may be limited due
to the overrepresentation of IDUs in our sample for
comparison purposes. The results of the total group are
not representative of problematic hard-drug users in
general, in contrast to the results concerning the sub-
groups of IDUs, FIDUs and NIDUs. Subgroup results
were confirmed by the members of the NIHR, which
support the generalizability of these results. Second, self-
reported data are used. The validity and reliability of
such data are considered to be questionable, although
several studies reported behavioural self-reports of prob-
lematic hard-drug users to be sufficiently reliable and of
good quality [61-63]. Finally, the cross-sectional study de-
sign does not allow drawing conclusions about causality.
Conclusions
This study was the first to investigate differences in
characteristics between NIDUs, FIDUS and IDUs in the
Netherlands, indicating that IDUs seem to be the group
with the least favourable characteristics (e.g. unstable
housing, illegal activities, no debt help). The large major-
ity of problematic hard-drug users—both injectors and
non-injectors—make use of low-threshold addiction care
facilities where respondents were interviewed. Increased
attention for physical and mental health within these fa-
cilities has resulted in harm reduction taking place at
different levels, as the facilities themselves as well as the
interventions within these facilities aim to reduce harm,
including improvements in health. Present findings on
public injecting and debt help support previous research
which emphasizes the potential of housing projects as a
component of harm reduction measures. Therefore, it is
important to continue housing policy measures for ex-
ample within the strategy plans for social relief of all of
the 43 so-called centre municipalities that cover theNetherlands. Access to housing for problematic hard-
drug users is part of this policy. It is worth mentioning
that residents of neighbourhoods where sheltered hous-
ing for problematic hard-drug users are located often
feared public nuisance and crime. Local research, espe-
cially in the city of Utrecht where sheltered housing
started in the Netherlands, showed that this fear is
largely ungrounded [31]. Last, it is recommended to put
intensive efforts into explicitly and directly targeting
IDUs. Although injecting is on the decline, injecting
drug use and public injecting still exist and remain a
threat to public health. Prevention of injecting and of
risks associated with injecting fits in with the increasing
attention for physical health in the Dutch low-threshold
addiction care and remains a topic of serious interest.
Endnotes
aWe collected the self-reported status of hepatitis B,
hepatitis C and HIV of the respondents; we are currently
comparing these self-reported data to registered data
within addiction care. The results are the topic of a
paper in preparation.
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